



Universiteit
Leiden
The Netherlands

The quest for broad-spectrum coronavirus inhibitors

Lima Leite Ogando, N.S.

Citation

Lima Leite Ogando, N. S. (2021, October 12). *The quest for broad-spectrum coronavirus inhibitors*. Retrieved from <https://hdl.handle.net/1887/3217007>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3217007>

Note: To cite this publication please use the final published version (if applicable).

The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2

Natacha S. Ogando, Jessika C. Zevenhoven-Dobbe, Yvonne van der Meer,
Peter J. Bredenbeek, Clara C. Posthuma^{§#} & Eric J. Snijder^{§#}

Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands

[#] Present address: Netherlands Commission on Genetic Modification, Bilthoven, The Netherlands

#authors contributed equally

Published in Journal of Virology

doi.org/10.1128/JVI.01246-20

ABSTRACT

Coronaviruses (CoVs) stand out for their large RNA genome and complex RNA-synthesizing machinery comprising 16 nonstructural proteins (nsps). The bifunctional nsp14 contains 3'-to-5' exoribonuclease (ExoN) and guanine-N7-methyltransferase (N7-MTase) domains. While the latter presumably supports mRNA capping, ExoN is thought to mediate proofreading during genome replication. In line with such a role, ExoN-knockout mutants of mouse hepatitis virus (MHV) and severe acute respiratory syndrome coronavirus (SARS-CoV) were previously reported to have crippled but viable hypermutation phenotypes. Remarkably, using reverse genetics, a large set of corresponding ExoN knockout mutations was now found to be lethal for another *Betacoronavirus*, Middle East respiratory syndrome coronavirus (MERS-CoV). For 13 mutants, viral progeny could not be recovered, unless – occasionally – reversion had first occurred. Only a single mutant was viable, likely because its E191D substitution is highly conservative. Remarkably, also a SARS-CoV-2 ExoN knockout mutant was found unable to replicate, resembling observations previously made for *Alphacoronavirus* and *Gammacoronavirus*, but starkly contrasting with the documented phenotype of ExoN knockout mutants of the closely related SARS-CoV. Subsequently, we established in vitro assays with purified recombinant MERS-CoV nsp14 to monitor its ExoN and N7-MTase activities. All ExoN knockout mutations that proved lethal in reverse genetics were found to severely decrease ExoN activity, while not affecting N7-MTase activity. Our study strongly suggests CoV nsp14 ExoN to have an additional function, which apparently is critical for primary viral RNA synthesis and thus differs from the proofreading function that – based on previous MHV and SARS-CoV studies – was proposed to boost longer-term replication fidelity.

IMPORTANCE

The bifunctional nsp14 subunit of the coronavirus replicase contains 3'-to-5' exoribonuclease (ExoN) and guanine-N7-methyltransferase domains. For the betacoronaviruses MHV and SARS-CoV, ExoN was reported to promote the fidelity of genome replication, presumably by mediating a form of proofreading. For these viruses, ExoN knockout mutants are viable while displaying an increased mutation frequency. Strikingly, we now established that the equivalent ExoN knockout mutants of two other betacoronaviruses, MERS-CoV and SARS-CoV-2, are non-viable, suggesting an additional and critical ExoN function in their replication. This is remarkable in light of the very limited genetic distance between SARS-CoV and SARS-CoV-2, which is highlighted, for example, by 95% amino acid sequence identity in their nsp14 sequences. For (recombinant) MERS-CoV nsp14, both its enzymatic activities were evaluated using newly developed in vitro assays that can be used to characterize these key replicative enzymes in more detail and explore their potential as target for antiviral drug development.

INTRODUCTION

RNA viruses commonly exhibit high mutation rates, a feature attributed to the relatively poor fidelity of their RNA-dependent RNA polymerase (RdRp) and the fact that nucleotide incorporation errors go uncorrected. This lack of proofreading contributes to the generation of ‘quasispecies’ populations, clouds of genome sequence variants that are subject to continuous natural selection [1-3]. On the one hand, their genetic heterogeneity allows RNA viruses to rapidly adapt to changing circumstances, in order to overcome environmental challenges such as host switching, antiviral drug treatment, or host immune responses [4, 5]. On the other hand, the accumulation of an excessive number of deleterious mutations can result in ‘error catastrophe’ and, consequently, in the extinction of a viral species [6-8]. In order to balance these opposing principles, RNA viruses are thought to operate close to their so-called ‘error threshold’, while balancing the interdependent parameters of replication fidelity, genome size, and genome complexity [9, 10]. This interplay is thought to have restricted the expansion of RNA virus genome sizes, which are below 15 kilobases (kb) for most RNA virus families [10-12].

The largest RNA virus genomes currently known are found in the order *Nidovirales*, which includes the *Coronaviridae* family and also the recently discovered planarian secretory cell nidovirus (PSCNV; [12, 13]), which has the largest RNA genome identified thus far (41.1 kb). One of the molecular mechanisms potentially driving the unprecedented expansion of nidovirus genomes was discovered about 17 years ago, during the in-depth bioinformatics analysis of the genome and proteome of the severe acute respiratory syndrome coronavirus (SARS-CoV). During this analysis, Alexander Gorbalenya and colleagues identified a putative 3'-to-5' exoribonuclease (ExoN) signature sequence in the N-terminal domain of nonstructural protein 14 (nsp14), a subunit of the large replicase polyprotein encoded by CoVs and related large-genome nidoviruses. Strikingly, this ExoN domain was found to be lacking in the replicases of nidoviruses with small(er) genomes (specifically, arteriviruses), and therefore it was proposed that the enzyme may provide a form of ‘proofreading activity’ that could have promoted the expansion of large nidoviral genomes to their current size [10-12, 14]. Comparative sequence analysis with cellular homologs classified the nidoviral/CoV ExoN domain as a member of the superfamily of DEDDh exonucleases, which also includes the proofreading domains of many DNA polymerases as well as other eukaryotic and prokaryotic exonucleases [15]. These enzymes catalyze the excision of nucleoside monophosphates from nucleic acids in the 3'-to-5' direction, using a mechanism that depends on two divalent metal ions and a reactive water molecule [16-18]. Five conserved active site residues arranged in three canonical motifs (I, II, and III; Fig. 1) orchestrate ExoN activity [14, 19-21]. Additionally,

the domain incorporates two zinc finger (ZF) motifs [10], ZF1 and ZF2 (Fig. 1), that were hypothesized to contribute to the structural stability and catalytic activity of ExoN, respectively [20].

The predicted 3'-to-5' exoribonuclease activity of the CoV ExoN domain was first confirmed *in vitro*, in biochemical assays using recombinant SARS-CoV nsp14 and different synthetic RNA substrates [19]. Originally, residues D90/E92 (motif I), D243 (motif II), and D273 (motif III) were identified as putative active site residues of SARS-CoV ExoN [14, 19]. However, the SARS-CoV nsp14 crystal structure revealed E191 rather than D243 to be the acidic active residue in motif II, demonstrating that ExoN is in fact a DEEDh enzyme [20]. By using reverse genetics for the *Alphacoronavirus* human coronavirus 229E (HCoV-229E), Minskaia *et al.* demonstrated that inactivation of the ExoN active site results in failure to recover infectious viral progeny [19]. Interestingly, a quite different phenotype was described for the corresponding ExoN-knockout mutants of two betacoronaviruses, mouse hepatitis virus (MHV) and SARS-CoV. While ExoN inactivation decreased replication fidelity in these viruses, conferring a 'mutator phenotype', the mutants were viable, both in cell culture [22, 23] and in animal models [24]. These findings suggested that ExoN may indeed be part of an error correction mechanism. Subsequently, the ability of ExoN to excise 3'-terminal mismatched nucleotides from a double-stranded (ds) RNA substrate was demonstrated *in vitro* using recombinant SARS-CoV nsp14 [25]. Furthermore, this activity was shown to be strongly enhanced (up to 35-fold) by the addition of nsp10, a small upstream subunit of the CoV replicase [26]. The two subunits were proposed to operate, together with the nsp12-RdRp, in repairing misincorporations that may occur during CoV RNA synthesis [21, 27]. In cell culture, MHV and SARS-CoV mutants lacking ExoN activity exhibit increased sensitivity to mutagenic agents like 5-fluoracil (5-FU), compounds to which the wild-type virus is relatively resistant [28, 29]. Recently, ExoN activity was also implicated in CoV RNA recombination, as an MHV ExoN knockout mutant exhibited altered recombination patterns, possibly reflecting its involvement in other activities than error correction during CoV replication and subgenomic mRNA synthesis [30]. Outside the order *Nidovirales*, arenaviruses are the only other RNA viruses known to employ an ExoN domain, which is part of the arenavirus nucleoprotein and has been implicated in fidelity control [31] and/or immune evasion, the latter by possibly degrading viral dsRNA [32, 33]. Based on results obtained with TGEV and MHV ExoN knockout mutants, also the CoV ExoN activity was suggested to counteract innate responses [34, 35].

In the meantime, CoV nsp14 had been proven to be a bifunctional protein by the discovery of a guanine-N7-methyltransferase (N7-MTase) activity in its C-terminal domain [36] (Fig. 1). This enzymatic activity was further corroborated *in vitro*, using biochemical assays with purified

recombinant SARS-CoV nsp14. The enzyme was found capable of methylating cap analogues or GTP substrates, in the presence of S-adenosyl methionine (SAM) as methyl donor [36, 37]. The N7-MTase was postulated to be a key factor for equipping CoV mRNAs with a functional 5'-terminal cap structure, as guanine-N7-methylation is essential for cap recognition by the cellular translation machinery [25]. Although the characterization of the nsp14 N7-MTase active site and reaction mechanism was not completed, alanine scanning mutagenesis and *in vitro* assays with nsp14 highlighted several key residues (Fig. 1) [36, 38, 39]. Moreover, crystal structures of SARS-CoV nsp14 in complex with its nsp10 co-factor (PDB entries 5C8U and 5NFY) revealed several unique structural and functional features [20, 21]. These combined structural and biochemical studies confirmed that the two enzymatic domains of nsp14 are functionally distinct [36] and physically independent [20, 21]. Still, the two activities are structurally intertwined, as it seems that the N7-MTase activity depends on the integrity of the N-terminal ExoN domain, whereas the flexibility of the protein is modulated by a hinge region connecting the two domains [21].

Coronaviruses are abundantly present in mammalian reservoir species, including bats, and pose a continuous zoonotic threat [40-43]. To date, seven CoVs that can infect humans have been identified, and among these the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently causing an unprecedented pandemic outbreak. The previous zoonotic CoV to emerge, in 2012, was the Middle East respiratory syndrome coronavirus (MERS-CoV) [44]. Due to its transmission from dromedary camels and subsequent nosocomial transmission, MERS-CoV continues to circulate and cause serious human disease, primarily in the Arabian peninsula [45]. Occasional spread to other countries has also occurred, including an outbreak with 186 confirmed cases in South Korea in 2015 [46-48]. Like SARS-CoV, SARS-CoV-2, and MHV, MERS-CoV is classified as a member of the *Betacoronavirus* genus, although it belongs to a different lineage (subgenus) of that cluster [49, 50]. The current lack of approved therapeutics and vaccines to prevent or treat CoV infections, as well as the general threat posed by emerging CoVs, necessitates the further in-depth characterization of CoV replication and replicative enzymes. In this context, the quite different phenotypes described for ExoN knockout mutants of other CoVs (see above) prompted us to study the importance of this enzyme for MERS-CoV replication. To this end, using both reverse genetics and biochemical assays with recombinant nsp14, we engaged in an extensive site-directed mutagenesis study, targeting all active site motifs of the MERS-CoV ExoN domain. Strikingly, in contrast to what was observed for two other betacoronaviruses, MHV and SARS-CoV, our studies revealed that ExoN inactivation severely impacts MERS-CoV replication, resulting in failure to recover viable progeny. While completing our MERS-CoV nsp14 studies, given the developing pandemic, we

also evaluated the impact of ExoN inactivation (using a D90A/E92A ExoN motif I double mutant) on SARS-CoV-2 replication and viability. Given the close phylogenetic relationship between SARS-CoV and SARS-CoV-2, reflected for example in 95% nsp14 amino acid identity [51], we were highly surprised to find that – as for our MERS-CoV ExoN knockout mutants – it was not possible to rescue viable progeny for this SARS-CoV-2 mutant in which two key residues of the ExoN active site were mutated. Our biochemical evaluation of MERS-CoV nsp14 mutants suggested that this phenotype is not caused by inadvertent side-effects of ExoN inactivation on N7-MTase activity. Our combined data suggest that CoV ExoN and/or nsp14 play a more direct and fundamental role in CoV RNA synthesis than merely safeguarding the longer-term fidelity of replication, and can thus be considered a prominent target for the development of antiviral drugs.




Fig. 1. Alignment of nsp14 amino acid sequences from selected coronaviruses. Sequences of the ExoN and N7-MTase domains in MERS-CoV (NC_019843); SARS-CoV (NC_004718); SARS-CoV-2 (NC_045512.2); MHV (NP_045298); HCoV-229E (NC_002645); TGEV (AJ271965); and IBV (NP_040829) were used for the analysis. The different domains indicated on the top are based on the SARS-CoV-nsp14 secondary structure (PDB 5NFY (21)). Fully conserved residues are boxed in dark grey with white letters (above 70% conservation), whereas partially conserved residues are displayed in lighter shades of grey. Catalytic residues and residues involved in formation of zinc fingers are marked with asterisks and circles, respectively. Full circles indicate zinc fingers targeted by

mutagenesis (Fig. 2A) while two black arrows identify the two N7-MTase domain residues mutated to generate the MTase negative control used in biochemical assays. The alignment was generated using Clustal Omega [52] and edited using Jalview version 2.11 [53].

RESULTS

ExoN inactivation is lethal for MERS-CoV

Previous studies into CoV ExoN function involved its biochemical characterization (based almost exclusively on the SARS-CoV version of the enzyme) and the phenotypic analysis of (predicted) ExoN knockout virus mutants, generated using reverse genetics approaches. The latter studies yielded replication-incompetent ExoN knockout mutants for the alphacoronaviruses HCoV-229E [19] and transmissible gastroenteritis virus (TGEV) [34]. However, the equivalent mutants of the betacoronaviruses SARS-CoV and MHV-A59 were somewhat crippled but clearly viable, while displaying a 15- to 20-fold increased mutation rate [22, 23]. An alignment of CoV nsp14 amino acid sequences is presented in Fig. 1, including SARS-CoV-2, which emerged in humans during the course of this project. It highlights the key motifs/residues of the two enzymatic domains of nsp14, as well as other structural elements, like the nsp10 binding site, the hinge region connecting the ExoN and N7-Mtase domains, and three previously identified nsp14 zinc finger domains [20, 21]. The alignment also illustrates the generally high degree of nsp14 sequence conservation across different CoV (sub)genera. In the present study, we targeted all five predicted active site residues of the MERS-CoV ExoN domain (D90, E92, E191, D273, and H268) by replacing them with alanine as well as more conservative substitutions (D to E or Q; E to D or Q). This yielded a total of 14 ExoN active site mutants (Fig. 2A), including the D90A/E92A motif-I double mutant (DM) that was frequently used as prototypic viable ExoN knockout mutant in MHV and SARS-CoV studies.

A BAC-based MERS-CoV reverse genetics system [54, 55], based on the sequence of the EMC/2012 isolate of MERS-CoV [56], served as the starting point to evaluate our ExoN mutants by transfection of full-length RNA that was obtained by *in vitro* transcription using T7 RNA polymerase. Transcripts were electroporated into BHK-21 cells, which lack the DPP4 receptor required for natural MERS-CoV infection [57, 58] but are commonly used to launch engineered CoV mutants because of their excellent survival of the electroporation procedure [19, 22, 23, 34, 54, 59]. As BHK-21 cells have a severely compromised innate immune response [60], they would seem an appropriate cell line to launch ExoN knockout mutants also in case the enzyme would be needed to counter innate immunity [34, 35]. To amplify any progeny virus released, transfected BHK-21 cells were mixed with either innate immune-deficient (Vero) or -competent (HuH7) cells, which both are naturally susceptible to MERS-CoV infection.

In stark contrast to what was previously described for MHV and SARS-CoV, mutagenesis of ExoN active site residues was found to render MERS-CoV non-viable. When cell cultures (BHK-21 mixed with Vero or HuH7 cells) were analyzed by immunofluorescence microscopy at 2 days post transfection (d p.t.), using antibodies recognizing dsRNA and nsp4, abundant signal and virus spread were always observed for wild-type MERS-CoV and the E191D mutant.




Fig. 2. MERS-CoV ExoN knockout mutants are non-viable. (A) Phenotype of MERS-CoV nsp14 ExoN mutants used in this study, scored at 2 d p.t. (B) Comparison of plaque phenotype of selected ExoN mutants in HuH7 cells. Plaque assays were performed using supernatants harvested from transfected cell cultures at 3 d p.t., which were diluted 10⁻⁴ for wt and mutant E191D, and used in undiluted form for the D90A/E92A ExoN knockout double mutant (DM) and the H229C ZF1 mutant. (C) Immunolabeling (2 d p.t.) of cell cultures consisting of a mixture of (non-susceptible) BHK-21 cells transfected with in vitro-made full-length MERS-CoV RNA and susceptible (DPP4-expressing) Vero cells used to amplify any infectious progeny released from the transfected BHK-21 cells. Images shown are for wt virus, the DM mutant, and the H229C mutant. Cells were labeled for dsRNA (green) and nsp4 (red). Bar is 100 μ m

For the other 13 mutants tested, some labeling was generally observed in a low percentage (less than 2%) of the cells (Fig. 2C, middle panel), usually in the form of single positive cells or a few positive cells together. However, virus spreading across the dish was not observed regardless whether Vero or HUH7 cells were used for propagation of recombinant virus progeny, unless reversion had first occurred (see Discussion). In line with these observations, infectious progeny could not be detected when transfected cell culture supernatants harvested at 3 or 6 d p.t. were analyzed in plaque assays (Fig. 2 and data not shown). The single exception was the mutant carrying the conservative E191D replacement in ExoN motif II (Fig. 1), which was alive but somewhat crippled, as will be discussed in more detail below. These results were consistent across a large number of independent repeats (>10 for several of the mutants; Fig. 2A), performed with RNA transcribed from independently engineered (and fully sequenced) duplicate full-length cDNA clones. The non-viable phenotype of MERS-CoV ExoN mutants in both cell types suggests that innate immune responses did not influence the outcome of these experiments.

Co-expression of the viral nucleocapsid (N) protein has been reported to boost the transfection efficiency of full-length CoV RNA transcripts [61-63]. In an ultimate attempt to rescue progeny for our non-viable MERS-CoV mutants, an *in vitro* made mRNA expressing the MERS-CoV N protein gene mutant was co-transfected with nsp14 mutant or wild type (wt) full-length RNA. This modification indeed somewhat increased the BHK-21 transfection rate, as monitored by performing infectious center assays with recombinant wt MERS-CoV-transfected cells (data not shown). However, it did not result in the recovery of infectious progeny for any of six non-viable mutants tested (D90E, E191A, D273A, H268A, DM, C210H), unless (occasionally) reversion had first occurred, as confirmed by RT-PCR amplification and sequencing of the nsp14-coding region.

ExoN inactivation is also lethal for SARS-CoV-2

During the final stage of this study, given the ongoing pandemic, we evaluated whether ExoN inactivation also affects SARS-CoV-2 replication. This was not expected given the viable phenotype of SARS-CoV ExoN knockout mutants and the close relationship between that virus and SARS-CoV-2 [43, 50], which is for example reflected in nsp14 amino acid sequences being ~95% identical between the two viruses [51]. Four independently engineered and fully sequenced SARS-CoV-2 BAC clones were used to transcribe full-length RNA carrying the D90A/E92A double mutation in ExoN motif I, which has been used in many studies with MHV and SARS-CoV ExoN knockout mutants [23, 28, 29]. These transcripts were transfected into SARS-CoV N protein-expressing BHK-21 cells [61], in the presence or absence of a synthetic

mRNA expressing the SARS-CoV-2 N protein. Subsequently, the transfected cells were mixed (1:1) with Vero E6 cells to support propagation of any viable progeny virus. Wild-type SARS-CoV and its corresponding (viable) ExoN knockout mutant (D90A/E92A; DM) were taken along as positive controls in these experiments. Surprisingly, using culture supernatant harvested at 3 or 6 d p.t., viable progeny could not be recovered for the SARS-CoV-2 DM mutant in any of the four independent repeats (Fig. 3). In contrast, for SARS-CoV, already at 2 d p.t. both the wild-type and ExoN knockout mutant produced abundant progeny, although the plaque phenotype and titers (1.5- to 2-log difference) of the ExoN knockout mutant were clearly reduced compared to the parental virus (Fig. 3A). As for the corresponding MERS-CoV mutant, immunofluorescence microscopy revealed some signal for the SARS-CoV-2 DM mutant in a low percentage of the cells by 2 d p.t. (Fig. 3B), but virus spreading was not observed up to 6 d p.t. These results highlight that the impact of ExoN inactivation on general viability can be very different, even between two closely related CoVs.




Fig. 3. SARS-CoV-2 ExoN knockout mutant is non-viable. (A) Plaque phenotype of wt SARS-CoV (left) and SARS-CoV-2 (right) and their corresponding ExoN motif-I knockout double mutants (DM, D90A/E92A) in Vero E6 cells. Plaque assays were performed using supernatants harvested from transfected cell cultures at 2 d p.t. for SARS-CoV and 3 d p.t for SARS-CoV-2. Samples were diluted 10⁻⁶ for SARS-CoV wt, 10⁻⁵ for SARS-CoV-2 wt and SARS-CoV DM, and 10⁻¹ for the SARS-CoV-2 DM mutant. (B) Immunolabeling (2 d p.t.) as described in Fig. 2C, but now using Vero E6 cells for amplification of SARS-CoV-2 progeny released from BHK-21 cells transfected with wt (top) or DM (bottom) full-length RNA. Bar is 100 μ m.

ExoN inactivation abrogates detectable MERS-CoV RNA synthesis

For a selection of MERS-CoV ExoN knockout mutants, intracellular RNA was isolated from transfected cell cultures at 2 d p.t. and analyzed by hybridization and RT-qPCR to more rigorously measure viral RNA synthesis (Fig. 4). In this analysis, a non-viable MERS-CoV mutant with an in-frame 100-aa deletion in the nsp12-RdRp domain was used as a negative control (NC) for viral RNA synthesis, in order to assess and correct for the detection of any residual full-length RNA transcript that might still be present at this timepoint after transfection. Upon direct in-gel hybridization analysis using a ^{32}P -labeled probe recognizing the 3' end of all viral mRNAs, the characteristic nested set of MERS-CoV transcripts could only be detected for the E191D mutant and the wt control (Fig. 4). Even after a 28-day exposure of the phosphor imager screen (data not shown), signal could not be detected for any of the other mutants. The lack of detectable MERS-CoV-specific RNA synthesis was further confirmed using RT-PCR assays specifically detecting genomic RNA and subgenomic mRNA₃. RNA accumulation was evaluated at 1 and 2 d p.t. for seven selected ExoN active site mutants (D90A, D90E, E191A, E191D, D273A, H268A, DM) using samples from two independent experiments both comprising duplicate transfections for each mutant. Again, MERS-CoV-specific genomic and subgenomic RNA synthesis was only detected for the E191D mutant and the wt virus control (data not shown). For all other mutants, the RT-PCR assays yielded Ct values in the range obtained for samples from mock-infected cells and the replication-deficient NC mutant. In conclusion, with the exception of E191D (see below), all our engineered ExoN active site mutations abrogated detectable viral RNA synthesis, suggesting that in the case of MERS-CoV – and likely also SARS-CoV-2 – the enzyme is indispensable for basic productive replication in cell culture.

Characterization of rMERS-CoV-nsp14-E191D replication kinetics and 5-FU sensitivity

Among our MERS-CoV ExoN active site mutants, only the E191D mutant yielded viable progeny (Fig. 2). This mutant appeared to be genetically stable as the substitution was preserved upon multiple consecutive passages in HuH7 or Vero cells (data not shown). Interestingly, the E191D mutation transforms the DEEDh catalytic motif into the DEDDh motif that is characteristic for members of the exonuclease family to which the CoV ExoN belongs [64]. In fact, when comparing ExoN sequences from different nidovirus taxa [14, 19], the equivalent of E191 alternates between E and D [65], in line with the observation that this mutation is tolerated in MERS-CoV ExoN.

To characterize the E191D mutant in more detail, its replication and fitness in cell culture were analyzed. Full-length genome sequencing of passage 2 of the E191D mutant virus revealed

that it had acquired two additional mutations when compared with the recombinant wt control: a synonymous mutation in the nsp2-coding region (U→C at nt position 2,315) and a non-synonymous mutation (C→A at nt position 6,541) specifying an A1235D substitution in the *Betacoronavirus*-specific marker (βSM) domain of nsp3, which has been predicted to be a non-enzymatic domain [66] and is absent in *Alphacoronavirus* and *Deltacoronavirus* genus [67, 68]. Thus, we assumed that any changes in viral replication were likely caused by the E191D mutation in nsp14 ExoN. The same virus stock was used to assess growth kinetics in HuH7 cells (Fig. 5B) and Vero cells (Fig. 5A), which were found to be quite similar for wt and mutant virus. Still, the E191D mutant was found to be somewhat crippled, yielding smaller plaque sizes and somewhat lower progeny titers in HuH7 cells (Fig. 5B-C and 2B), but not in Vero cells (Fig. 5A).




Fig. 4. Impact of ExoN inactivation on intracellular MERS-CoV RNA synthesis. In-gel hybridization analysis of intracellular RNA isolated after 2 or 3 d p.t. of transfected BHK-21 cells, which were subsequently mixed with HuH7 or Vero cells as indicated. Purified RNA was separated in an agarose gel and probed with a radiolabeled oligonucleotide probe recognizing the MERS-CoV genome and subgenomic mRNAs.

We next examined the sensitivity of E191D and wt virus to the mutagenic agent 5-FU, which intracellularly is converted into a nucleoside analogue that is incorporated into viral RNA [69, 70]. Previously, MHV and SARS-CoV ExoN knockout mutants were found to exhibit increased sensitivity to 5-FU treatment, in particular in multi-cycle experiments, which was attributed to a higher mutation frequency in the absence of ExoN-driven error correction [28]. We employed this same assay to assess the phenotype of the E191D mutant in more detail, by performing plaque assays in HuH7 cells in the presence of increasing 5-FU concentrations (Fig. 5C) and by growing mutant and wt virus in the presence of increasing 5-FU concentrations (Fig. 5D). No cytotoxicity was observed in HuH7 cells following treatment with up to 400 μM 5-FU (data not shown).




Fig. 5. Characterization of growth kinetics of rMERS-nsp14-E191D and its sensitivity to 5-FU treatment. (A) Vero cells or (B) HuH7 cells were infected at an m.o.i. of 3, supernatant was harvested at the indicated time points, and viral progeny titers were measured by plaque assay from two independent experiments using duplicates ($n=4$; mean $\pm$ sd is presented). (C) Plaque phenotype in HuH7 cells of rMERS-CoV nsp14-E191D and wt control in the absence or presence of the mutagenic agent 5-FU. (D) Dose response curve of wt and E191D mutant MERS-CoV in the presence of 5-FU concentrations up to 400 μM (m.o.i. 0.1; $n=4$; mean $\pm$ sd is presented). Statistical significance of the difference with wt virus at each time point (A and B) or concentration (D) was assessed by paired t-test. *, $p<0.05$; **, $p<0.005$.

Plaque assays in HuH7 cells were performed for 3 days, using a standard inoculum of 30 p.f.u. and an increasing amount of 5-FU in the overlay. Similar dose-dependent reductions of plaque size were observed for E191D and wt virus, with E191D plaques being barely visible upon treatment with 200 μ M 5-FU (Fig. 5C). In an alternative experiment, Huh7 cells were infected with an m.o.i. of 0.1 and treated with a different 5-FU dose for 30 h, after which progeny virus titers were determined by regular plaque assay. Again, both viruses exhibited a similar concentration-dependent decrease of replication (Fig. 5D), although the E191D mutant appeared to be somewhat more sensitive to the mutagenic agent, yielding $\sim$ 1-log lower progeny titers than wt virus upon treatment with 5-FU concentrations between 100 and 400 μ M.

Taken together, these experiments demonstrated that overall replication of mutant E191D is only mildly affected and that it is somewhat more sensitive to 5-FU treatment than wt MERS-CoV. This phenotype is consistent with the bioinformatics-based prediction that a mutant nsp14 carrying this substitution may retain ExoN activity, as will be demonstrated below.

ExoN zinc finger motifs are important for viral replication

Studies addressing the structural biology and biochemistry of SARS-CoV nsp14 suggested that the two ZF motifs within the ExoN domain contribute to either its structural stability (ZF1) or catalytic activity (ZF2) [20, 21]. Moreover, mutagenesis studies of the MHV and TGEV ZF1 domain supported their importance for viral replication in cell culture [34, 59]. To study the impact of similar mutations on MERS-CoV replication, the nsp14 ZF1 and ZF2 domains were targeted with two mutations each and their impact on virus viability was evaluated as described above. Two ZF1 residues (C210 and H229) were mutated from H to C or vice versa, which could theoretically preserve the zinc-coordinating properties [71, 72]. Two residues of the non-classical ZF2 motif were also substituted (C261A and H264R) to evaluate the same ZF2 mutations previously analyzed by Ma *et al.*, leading to disruption of ExoN activity *in vitro* [20].

The four ZF virus mutants were launched as described above, after which a low level of replication could be observed only for the H229C ZF1 mutant (Fig. 2C), for which the 2 d p.t. harvest yielded very small plaques (Fig. 2B) and 2- to 4-log reduced progeny titers, depending on the experiment and time point of harvesting (data not shown). For this mutant, RNA synthesis could not be detected by hybridization analysis (Fig. 4), but synthesis of genomic and subgenomic RNA (mRNA3) was detected by RT-PCR in intracellular RNA samples harvested at 2 d p.t. (data not shown). A 6 d p.t. harvest was used for full genome sequencing by NGS, which confirmed the presence of the engineered nsp14 mutation in addition to the

appearance of some minor genetic variants (point mutations representing less than 15% of the total population) in different regions of the genome, including the ORF1a domains encoding for nsp3, nsp6, nsp8, and nsp9. Taken together, our observations indicate that the H229C mutant is viable but severely crippled. In combination with the fact that the other ZF mutations (C210H in ZF1, and C261A and H264R in ZF2) abolished MERS-CoV replication, our study establishes the importance of both ExoN ZF motifs for MERS-CoV viability.




Fig. 6. Expression and purification of recombinant MERS-CoV nsp14. N-terminally His-tagged wt and mutant MERS-CoV nsp14 (~55 kDa) was expressed in *E. coli*, affinity purified, and analyzed in a 10% SDS-PAGE gel that was stained with Coomassie Blue. The molecular masses of the protein marker (Invitrogen) are given in kDa..

Development of a MERS-CoV ExoN activity assay using recombinant nsp14

In order to assess the impact of mutations on nsp14's enzymatic activities, we set out to purify recombinant MERS-CoV nsp14 and develop an *in vitro* ExoN assay. Thus far, such an assay had only been described for the equivalent SARS-CoV protein [19, 20, 26, 73]. Wild-type and mutant MERS-CoV nsp14 proteins carrying an N-terminal His-tag were expressed in *E. coli* Rosetta (DE3) pLysS. Proteins were purified by immobilized metal affinity chromatography (IMAC) followed by size exclusion chromatography. Upon SDS-PAGE, the purified MERS-CoV nsp14 was consistently detected as a doublet (with the lower band being most abundant), migrating at the expected molecular mass of ~55 kDa (Fig. 6). As a positive control, we purified SARS-CoV nsp14 [26] and used it during optimization of the enzymatic assays for MERS-CoV nsp14. The substrate used for ExoN activity assays was a 5'-³²P-labeled 22-nucleotide (nt) long

synthetic RNA, as previously used in similar assays with SARS-CoV nsp14 (referred to as oligonucleotide H4 in [26]). Nucleotides 5-22 of this substrate are predicted to form a hairpin with a stem consisting of seven G-C base pairs and a loop of 4 As [26], while the remaining 4 nucleotides form a 5'-terminal single-stranded tail.

Previously, the ExoN activity of SARS-CoV nsp14 was found to be dramatically stimulated by the addition of nsp10 as co-factor [26]. Consequently, we also expressed and purified MERS-CoV nsp10 and optimized the ExoN assay by testing different molar ratios between nsp14 and nsp10 (Fig. 7A, left-hand side), different nsp14 concentrations (Fig. 7B, left-hand side), and by different incubation times (Fig. 8, left-hand side). MERS-CoV nsp14 ExoN activity was found to be stimulated by nsp10 in a dose-dependent manner (Fig. 7A), while nsp10 did not exhibit any nuclease activity by itself (Fig. 7B, nsp10 lane). The full-length substrate is more completely degraded when a fourfold (or higher) excess of nsp10 over nsp14 was used compared to the effect of merely increasing the nsp14 concentration in the assay (Fig. 7B). Different substrate degradation patterns were observed when comparing nsp14 alone with the nsp14-nsp10 in complex, which likely derived from structural and functional differences between these two nsp14 conformations. Similar observations were previously reported for SARS-CoV nsp14 [20, 21, 26] and recently for SARS-CoV-2 nsp14 [74]. When using an excess of nsp14 over nsp10, an intermediate (or mixed) pattern of degradation products was obtained (Fig. 7B), including an elevated amount of products with a length of 21-17 and 11-6 nt. Introduction of the D90A/E92A motif-I double substitution resulted in a major reduction of ExoN activity, although a certain level of residual activity was observed, in particular when using large amounts of nsp14 (Fig. 7B, right-hand side) or a relatively high nsp10:nsp14 ratio (Fig. 7A, right-hand side). Similar observations were previously made for SARS-CoV nsp14 [20, 26].

Using a 4:1 ratio of nsp10 versus nsp14, MERS-CoV ExoN activity was analyzed in a time-course experiment (Fig. 8). Over time, the full-length substrate was progressively converted to a set of degradation products in the size range of 6-18 nt. We anticipated that the structure of the H4 RNA substrate would change from a duplexed to a single-stranded conformation, upon digestion of one side of the hairpin's stem by ExoN's nuclease activity. As the ExoN enzymes of other CoVs were reported to prefer dsRNA substrates [19, 73], the degradation of the substrate might be slowed down substantially after removal of the first couple of nucleotides from its 3' end [26]. This would explain the abundant generation of degradation products of 16 and 17 nt in length (Fig. 7-9) and suggest that the preference for dsRNA substrates is indeed shared by MERS-CoV ExoN.

Degradation of the RNA substrate could be observed within 5 min and the full-length substrate was essentially gone after 30 min. A similar reaction with the nsp14 DM mutant resulted in only a small amount of substrate degradation after 90 min (Fig. 8, leftmost lane). Taken together, our results convincingly demonstrate the *in vitro* 3'-to-5' exonuclease activity of purified MERS-CoV nsp14. As in the case of the SARS-CoV enzyme, nsp10 is a critical co-factor that can strikingly upregulate MERS-CoV ExoN activity *in vitro*.




Fig. 7. Optimization of MERS-CoV nsp14 *in vitro* ExoN assay conditions. The substrate for the assay was a 22-nt long synthetic RNA (H4) that was 32P-labeled at its 5' terminus (*p-RNA). Cleavage products were separated by polyacrylamide gel electrophoresis and visualized by autoradiography. (A) Analysis of ExoN activity in the presence of an increasing amount of nsp10, using wt MERS-CoV-nsp14 (left) and the ExoN double knockout mutant (DM, D90A/E92A; right). The RNA substrate was hydrolyzed for 90 min at 37°C using a fixed concentration of nsp14 (200 nM) and an increasing nsp10 concentration, ranging from 0 to 1600 nM. (B) Evaluation of the ExoN activity of an increasing concentration (200 to 2000 nM) of wt or DM nsp14 in the presence of a fixed amount of nsp10 (200 nM).

MERS-CoV nsp10 modulates nsp14 ExoN activity

In order to investigate differences that might explain the variable phenotype of CoV ExoN knockout virus mutants, we compared ExoN activities between SARS-CoV and MERS-CoV

nsp14, using the optimized *in vitro* assay described above. An incubation time of 90 min was used, unless indicated otherwise. The nsp14 and nsp10 preparations of both viruses were first tested individually in an assay containing the H4 RNA substrate and Mg^{+2} ions [26, 75, 76]. As expected, this revealed only traces of exonuclease activity for both nsp14 proteins alone (Fig. 9, lanes 4 and 6). When the two proteins were combined in the same reaction, a strong increase of ExoN activity was observed for both nsp14-nsp10 pairs, with the SARS-CoV pair appearing to be somewhat more active than the MERS-CoV pair (Fig. 9, lanes 2 and 9).




Fig. 8. Time course analysis of the *in vitro* ExoN activity of MERS-CoV nsp14. The ExoN activity of different recombinant nsp14 proteins (wt, D90A/E92A, E191D and H229C) was evaluated by incubating 200 nM of nsp14 and 800 nM of nsp10 for 0, 5, 30, 60 and 90 min at 37°C. As controls, individual proteins (800 nM) were incubated for 90 min. For technical details, see the legend to Fig. 7.

The exchange of the SARS-CoV and MERS-CoV nsp10 co-factors revealed that they can cross-activate the ExoN activity of nsp14 from the other virus, although some changes in the pattern of degradation products were observed (Fig. 9, Lanes 1-2 and lanes 8-9). However, the residual ExoN activity of the motif I double mutant (DM) apparently was not affected by the choice of nsp10 co-factor (Fig. 9, compare lanes 11 and 12). The observed subtle changes in degradation product patterns are another indication that nsp10 modulates nsp14 ExoN activity, presumably using interaction surfaces that are well-conserved across CoV genera [75, 76].




Fig. 9. Cross-activation of the in vitro activity of SARS-CoV and MERS-CoV nsp14 by heterologous nsp10. The nsp10 co-factor was exchanged in ExoN assays performed with MERS-CoV and SARS-CoV nsp14, using a 1:4 ratio between nsp14 and nsp10 and a 90-min incubation at 37°C. For technical details, see the legend to Fig. 7..

ExoN activity of MERS-CoV active site and H229C mutants

Having established the optimal conditions for MERS-CoV ExoN *in vitro* activity, we evaluated the impact of a subset of the DEEDh active site mutations that were used during our reverse genetic analysis (Fig. 2A). For each mutant tested, two protein batches were purified and analyzed independently in duplicate using the same batch of MERS-CoV nsp10 for all assays. As can be seen in Fig. 10, replacement with Ala of each of the five active site residues resulted in a near-complete loss of ExoN activity, with the D90A, E92A, and H268A substitutions appearing to be slightly less detrimental than E191A and D273A. A clearly different result was again obtained with the E191D mutant, which displayed an activity level comparable to that of wt nsp14, corresponding with the properties of the corresponding virus mutant (Fig. 2, 4 and 5). Overall, the severe impact of active site mutations on ExoN activity was fully in line with the non-viable phenotypes observed for the same mutants when tested using reverse genetics (Fig. 2).

We also evaluated the impact of the H229C ZF1 mutation, which – despite its conservative nature - yielded a crippled mutant virus (Fig. 2), and of two N7-MTase mutations (to be discussed below). The N7-MTase mutants displayed wt nsp14-like ExoN activities (Fig. 10), suggesting that – as in SARS-CoV nsp14 - ExoN and N7-MTase activities are functionally separated [36]. Analyzing the substrate degradation pattern of the H229C mutant (Fig. 8) revealed that the enzyme was less efficient in its ability to degrade RNA when compared to wt nsp14. This can be seen, for example, when comparing the reaction products after 5-min assays in Fig. 8 and 10. A more detailed quantitative assessment of the activity level of nsp14 mutants is beyond the scope of this study. The H229C mutation clearly reduced ExoN activity *in vitro*, potentially by affecting the structure of the ExoN domain, as ZF1 is in close proximity of the nsp10 interaction surface [20]. However, a similar reduction of ExoN activity was observed for the E191D mutant (Fig. 8), which was much more viable than the H229C mutant in the context of our reverse genetics studies. This suggests that the H229C replacement may affect additional functions or interactions of the ExoN domain that are important for viral RNA synthesis and viability.




Fig. 10. In vitro ExoN activity of MERS-CoV nsp14 mutants. Residues from the DEDDh catalytic motif and ZF1 motif of the nsp14 ExoN domain and the nsp14 N7MTase domain were mutated as indicated. Assays were performed using a 1:4 ratio between nsp14 and nsp10 and a 90-min incubation at 37°C. For technical details, see the legend to Fig. 7.

ExoN mutations do not interfere with N7-MTase activity *in vitro*

The nsp14 N7-MTase activity is deemed essential for formation of a functional RNA cap, enabling the translation of CoV mRNAs and protecting them from degradation. Consequently, at least in theory, ExoN mutations could also be detrimental for virus replication if they would somehow affect the crucial enzymatic activity of the other nsp14 domain. In order to evaluate this possibility, the same recombinant protein preparations used for the ExoN assays (Fig. 6) were evaluated in an N7-MTase biochemical assay using the synthetic cap analogues GpppA and m7GpppA (control) as substrates. Moreover, nsp14 mutants R310A and D331A were used as negative controls in view of their predicted involvement in the binding of the triphosphate

moiety of the RNA chain and the methyl donor (S-adenosylmethionine; SAM), respectively [20, 26, 36]. In this assay, nsp14 can methylate GpppA by transferring the [^3H]CH $_3$ moiety provided by [^3H]SAM. The resulting radio-labelled m7GpppA product can be quantified using a DEAE filter-binding assay, followed by liquid scintillation counting, and data normalization against the activity of wt control protein [25].




Fig. 11. In vitro N7-MTase activity of MERS-CoV nsp14 mutants. The N7-MTase activity of recombinant nsp14 was analyzed in vitro by filter binding assay using synthetic cap analogues as substrate. (A) Increasing concentrations of MERS-CoV nsp14 were incubated with GpppA and m7GpppA in the presence of [^3H]SAM for 30 min. (B) The ability of nsp14 to methylate GpppA or m7GpppA was determined after reaction times between 0 and 120 min at 30°C. (C) The ability of nsp14 mutants to methylate GpppA was measured in four times in duplicate. Values were normalized to the wt control (n=8; mean $\pm$ sd are shown).

Recombinant MERS-CoV nsp14 was found to methylate GpppA, but not m7GpppA (Fig. 11A), which yielded a signal that was similar to the background signal in assays lacking nsp14 or substrate (data not shown). Methylation increased with time until reaching a plateau after

120 min (Fig. 11B). The N7-MTase activity of the various nsp14 mutants was compared with that of wt nsp14 after reaction times of 30 and 120 min (Fig. 11C). While the R310A and D331A control mutations fully inactivated the N7-MTase activity of MERS-CoV nsp14, none of the ExoN active site mutations tested was found to alter the enzyme's activity. These results again support the notion that ExoN and N7-MTase domains are functionally separated, as previously demonstrated for SARS-CoV-nsp14 [36]. We therefore conclude that the lethal impact of ExoN inactivation on MERS-CoV replication (Fig. 2A) cannot be attributed to inadvertent effects on the activity of the N7-MTase domain that is present in the same nsp14 replicase subunit.

DISCUSSION

In this study, we demonstrate that the impact of ExoN inactivation on virus viability and RNA synthesis distinguishes MERS-CoV and SARS-CoV-2 from two other betacoronaviruses, MHV and SARS-CoV. Whereas ExoN inactivation in the latter two viruses yields viable mutants that are only mildly crippled and exhibit a 'mutator phenotype' [22, 23, 29], both conservative and alanine substitutions of MERS-CoV ExoN catalytic residues abolished the recovery of infectious progeny (Fig. 2) and the detection of viral RNA synthesis (Fig. 4). The only exception was the conservative E191D mutant, which was found to exhibit near-wt ExoN activity (Fig. 7 and 10). Though limited in its scope, it is even more remarkable that our mutagenesis of SARS-CoV-2 yielded a very similar non-viable phenotype for an ExoN knockout mutant, in spite of the close relationship of this virus with SARS-CoV, for which ExoN knockout mutants are crippled but quite viable (Fig. 3). For most MERS-CoV ExoN knockout mutants and for the SARS-CoV-2 double mutant, immunofluorescence microscopy revealed some virus-specific signal in a few individual cells at 2 d p.t. (Fig. 2C and 3B), a time point at which wt viruses have already spread efficiently and infected all susceptible cells in the culture. The very limited labeling observed for mutant virus-transfected cultures is difficult to interpret and requires further analysis, but it suggests that viral RNA synthesis is not completely abrogated, at least not in all transfected cells, and likely explains that reversion occurred occasionally for several of the MERS-CoV single mutants late in the experiment.

Based on nsp14 conservation (Fig. 1) and the viable phenotype of SARS-CoV and MHV ExoN-knockout mutants, MERS-CoV and SARS-CoV-2 were expected to tolerate ExoN inactivation, in particular since the enzyme was proposed to improve the fidelity of CoV replication without being essential for RNA synthesis *per se* [10, 14, 21-23, 26, 29]. This notion is further supported by the fact that the CoV RdRp (nsp12) exhibits *in vitro* activity in the absence of nsp14 [27]. We therefore anticipated that an excess of deleterious mutations would first have to accumulate before becoming detrimental. Contrary to these expectations, an immediate lack

of viability was observed when MERS-CoV or SARS-CoV-2 ExoN knockout mutants were launched. It is noteworthy that similar observations were previously made for the corresponding ExoN knockout mutants of the alphacoronaviruses HCoV-229E [19] and TGEV [34], and the *Gammacoronavirus* avian infectious bronchitis virus (IBV) (E. Bickerton, S. Keep, and P. Britton, personal communication). Furthermore, in line with our observations, a recent report from the Denison laboratory - awaiting peer review – briefly mentions that also in their hands nsp14-ExoN catalytic mutants could not be rescued for both MERS-CoV and SARS-CoV-2 [30].

None of the ExoN mutations tested had a negative effect on the *in vitro* activity of the N7-MTase domain of nsp14, which is deemed essential for viral mRNA capping (Fig. 11). This is consistent with previous observations for SARS-CoV nsp14, in which the ExoN and N7-MTase activities were shown to be functionally distinct but structurally interconnected by a hinge region that confers flexibility [21, 36]. Given their unchanged N7-MTase activity, the non-viable phenotype of MERS-CoV ExoN active site mutants must be attributed to a negative effect on an additional and apparently critical function of the ExoN domain, which likely is directly involved in primary RNA synthesis rather than in (longer-term) fidelity control. At present we cannot explain, why SARS-CoV and MHV ExoN knockouts can apparently tolerate ExoN active site substitutions that are lethal to five other CoVs (including the closely related SARS-CoV-2). Within the *Betacoronavirus* group, in our experience, SARS-CoV and MHV display the most robust RNA synthesis and replication in cell culture when compared to MERS-CoV and SARS-CoV-2 [77-79], as also illustrated by the SARS-CoV and SARS-CoV-2 plaque phenotypes presented in Fig. 3. Possibly, the recovery of viable progeny depends on reaching a minimum level of RNA synthesis, which may somehow be achieved by only the most efficiently replicating CoVs. Admittedly, even bearing this possibility in mind, it remains difficult to reconcile the 1- to 2-log reduction of progeny titers observed for MHV and SARS-CoV ExoN-knockout mutants with the complete loss (> 6-log reduction) of infectious progeny observed for the ExoN-knockout mutants of the other CoVs.

In order to eliminate technicalities that might somehow prohibit the successful recovery of MERS-CoV ExoN knockout mutants and explain the phenotypic differences with other CoVs, we explored various details in the transfection protocol. This included the use of a DNA-launched system, similar to that used for TGEV [34], and the propagation of progeny virus in both innate immune-competent and -incompetent cells (Huh7 and Vero cells, respectively). However, this did not change the negative outcome of our transfection experiments, which were repeated more than 10 times for several of the non-viable mutants, always using wt and E191D MERS-CoV as positive controls that proved to be consistently viable. Next, we

performed experiments in which BHK-21 cells were co-transfected with a synthetic mRNA expressing the N protein, which has been reported to promote the recovery of recombinant CoVs [62, 63]. Indeed, judging from immunolabelings and early virus yields, such an effect could be observed, but it did not alter the outcome for the non-viable ExoN knockout mutants, and 3 d p.t. virus harvests continued to yield no plaques for both MERS-CoV and SARS-CoV-2. These combined observations strengthen our conclusion that – in addition to its proposed role as a proofreading enzyme – ExoN likely has an additional role in CoV RNA synthesis [65]. As reported for MHV and SARS-CoV ExoN mutants [23, 80], possible (late) reversion was observed for a few of our MERS-CoV ExoN active site mutants, specifically mutants E191A, D273E, D273A and in particular D90E, which had reverted by 6 d p.t. in four out of eight experiments. Together with the immunolabeling results presented in Fig. 2C, this suggests that these mutants (and perhaps others as well) exhibit a low residual level of RNA synthesis that is the basis for these low-frequency reversion events. Furthermore, in follow-up studies with the crippled H229C ZF1 mutant, a possible pseudo-revertant carrying a second-site mutation (Q19R) in nsp8 was identified in three independently obtained progeny samples, providing genetic support for an interaction between nsp8 and nsp14, which may be relevant in the context of the association of nsp14 with the tripartite RdRp complex consisting of nsp7, nsp8, and nsp12 [21, 27, 81-83]. Future studies will address the properties of these nsp14 ExoN knockout mutants and their (pseudo) revertants in more detail.

In the only viable MERS-CoV ExoN active site mutant obtained, E191D, the catalytic motif was changed from DEEDh to the DEDDh that is characteristic of all members of the exonuclease family that ExoN belongs to [14, 15, 84]. The growth of the E191D virus mutant was comparable to that of wt virus (Fig. 4A-B). Biochemical assays revealed that the E191D-ExoN enzyme is able to hydrolyze a dsRNA substrate with an activity level approaching that of the wt protein (Fig. 8 and 10). Although the E191D mutant was somewhat more sensitive to the mutagenic agent 5-FU (Fig. 5C-D) [28, 80], its ExoN activity does not appear to be dramatically altered by this conservative substitution in the active site.

For this study, we developed an *in vitro* assay to evaluate MERS-CoV ExoN activity using a largely double-stranded RNA substrate (Fig. 7, 8, and 10). As previously observed for SARS-CoV nsp14 [26], MERS-CoV ExoN activity was strongly enhanced by the presence of nsp10 (Fig. 9), in line with the formation of an nsp10:nsp14 heterodimer as observed in biochemical and structural studies [20, 26, 85]. Slightly different patterns of degradation of the H4 substrate were observed when comparing the SARS-CoV and MERS-CoV ExoN enzymes *in vitro*. Likewise, the exchange of the nsp10 co-factor for the nsp10 subunit of the other virus, using the same substrate and the same nsp10:nsp14 ratio (1:4; Fig. 9), resulted in a somewhat

different pattern of substrate degradation, suggesting minor differences in the interaction of the nsp10:nsp14 complex with this particular RNA substrate. Previously, it was demonstrated that nsp10 is interchangeable between CoV subgenera in its role as co-factor for the nsp16 2'-O-methyltransferase, which was attributed to the high level of conservation of the nsp10-nsp16 interaction surface [86]. As nsp14 and nsp16 share a common interaction surface on nsp10 [21, 26, 75], we explored whether a similar co-factor exchange was possible in the context of nsp14's ExoN activity, which was indeed found to be the case (Fig. 9). Structurally, nsp14 interacts with nsp10 figuratively similar to a "hand (nsp14) over fist (nsp10)" conformation [21]. Upon formation of this complex, nsp10 induces conformational changes in the N-terminal region of ExoN that adjust the distance between the catalytic residues in the back of the nsp14 palm and, consequently, impact ExoN activity [21]. The exchange of the nsp10 co-factor between the two betacoronaviruses might affect this conformation and, consequently, modulate the ExoN activity of the nsp14:nsp10 complex.

Alanine substitutions of active site residues severely reduced but did not completely abrogate the *in vitro* activity of MERS-CoV ExoN (Fig. 8-10), as previously shown for certain SARS-CoV nsp14 mutants [20, 36] and recently also for SARS-CoV-2 ([74], not peer reviewed). Based on the two-ion-metal catalytic mechanism underlying the exonuclease activity of DEDDh family members [17, 64] and the SARS-CoV nsp14 structure, it was predicted that the various ExoN motifs contribute differently to the excision of nucleosides monophosphates [20, 21]. Mutation of ExoN catalytic residues can alter ion binding [31] or disturb the fragile chemical equilibrium, as shown for conservative mutations (corresponding to E191D and D273E) in the Klenow fragment, a member of the DEDDh exonuclease family, which reduced ExoN activity by >96% [87]. In general, all DEEDh mutations that yielded non-viable virus mutants exhibited similarly low levels of residual ExoN activity *in vitro* (Fig. 10), indicating that each of these residues is important for catalysis.

Our study suggests that, in addition to the active site residues, also other motifs in MERS-CoV ExoN are important for virus viability, specifically the two ZF motifs that were probed using two point mutations each (Fig. 2A). In previous ZF1 studies, a mutation equivalent to H229A caused solubility issues during expression of recombinant SARS-CoV nsp14 [20] and resulted in a partially active ExoN in the case of white bream virus, a tobanivirus that also belongs to the order *Nidovirales* [88]. It was suggested that ZF1 contributes to the structural stability of ExoN, as it is close to the surface that interacts with nsp10 [20]. Here, we demonstrate that the more conservative H229C replacement, which converts ZF1 from a non-classical CCCH type ZF motif into a classical CCCC type [71], was tolerated during recombinant protein expression and yielded an ExoN that is active *in vitro* (Fig. 8). This likely contributed to the fact

that the H229C virus mutant retained a low level of viability (Fig. 2 and data not shown). Nevertheless, its overall crippled phenotype and the non-viable phenotype of mutant C201H clearly highlighted the general importance of ZF1 for virus replication. In contrast, the corresponding TGEV mutant (ZF-C) was not strongly affected and could be stably maintained over several passages [34]. The reverse genetics data suggest that ZF2, which is in close proximity to ExoN catalytic residues [20], is equally important, although technical complications with expression of the C261A and H264R nsp14 mutants prevented us to perform *in vitro* activity assays.

Like the ExoN domain of the arenavirus nucleoprotein [32, 33], the CoV ExoN was proposed to be involved in innate immune evasion [34, 35, 89], possibly by degrading viral dsRNA that in the case of CoVs is confined to characteristic double-membrane vesicles [90-92]. For TGEV, this suggestion was based on the reduced accumulation of dsRNA by the ZF-C mutant, which however remains to be characterized in more detail. In the absence of a TGEV ExoN activity assay, and in view of our data for the equivalent MERS-CoV ZF1 mutant, it seems premature to assume that the reduced levels of dsRNA in infected cells are caused by increased exonuclease activity of the ZF-C ExoN mutant [34].

In general, the properties of viable CoV ExoN mutants warrant further analysis. In future studies, the repertoire of residues probed by site-directed mutagenesis could be extended beyond active site and ZF motifs, which may help in particular to establish how directly reduced ExoN activity, primary viral RNA synthesis, and enhanced innate responses are interconnected. Regardless of its possible interactions with host cell pathways, nsp14 clearly is a key subunit of the multi-enzyme complex that drives CoV genome replication, subgenomic RNA synthesis, and RNA recombination. Understanding the structure-function interplay between ExoN and other (viral and/or host) components will be key to elucidating its role in CoV RNA synthesis and evolution [93, 94]. Taking into account the current SARS-CoV-2 pandemic, understanding the phenotypic differences between ExoN knockout mutants of different CoVs may contribute to the design of improved antiviral approaches, including those relying on 'lethal mutagenesis' or direct interference with viral RNA synthesis.

MATERIALS AND METHODS

Cell culture

Baby hamster kidney cells (BHK-21; ATCC CCL10), Vero E6, Vero (ATCC CCL81) and HuH7 cells were cultured as described previously [78, 95]. Vero and Vero E6 cells were kindly provided by the Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands, and HuH7 cells by Dr. Ralf Bartenschlager, Heidelberg University, Germany. For transfections, cells

were maintained in Eagle's minimal essential medium (EMEM; Lonza) with 8% fetal calf serum (FCS; Bodinco) supplemented with 100 IU/ml of penicillin and 100 µg/ml of streptomycin (Sigma), and 2 mM L-Glutamine (PAA Laboratories), and incubated at 37 °C with 5% CO₂. Infection of Vero, Vero E6 and HuH7 cells was carried out in EMEM containing 2% FCS. SARS-CoV and SARS-CoV-2 were grown in Vero E6 cells and MERS-CoV in Vero and HuH7 cells.

Reverse genetics

Mutations in the MERS-CoV nsp14-coding region were engineered in a bacterial artificial chromosome (BAC) vector [54, 55] containing a full-length cDNA copy of MERS-CoV strain EMC/2012 [44, 56], by two-step *en passant* recombineering in *E. coli* [96]. For SARS-CoV and SARS-CoV-2, a BAC DNA vector containing a full-length cDNA copy of the SARS-CoV Frankfurt-1 sequence [97] or SARS-CoV-2 BetaCoV/Wuhan/IVDC-HB-01/2019 [61, 98] were used. When designing the primers, a translationally silent marker mutation was introduced near the site of mutagenesis in order to differentiate between the occurrence of reversion and (possible) contamination with parental virus. For each mutation, two mutant BACs were isolated independently, the nsp14-coding region was verified by sequencing, and both BACs were used for *in vitro* run-off transcription and virus launching.

Approximately 5 µg of BAC DNA was linearized with *NotI* and full-length RNA was obtained by *in vitro* transcription with T7 RNA polymerase followed by lithium chloride precipitation according to the manufacturer's protocol (mMessage-mMachine T7 Kit; Ambion). For some of the MERS-CoV and the SARS-CoV-2 transfections, synthetic mRNAs expressing the respective N proteins were generated as described previously [62, 63] and 10 µg was co-transfected with the corresponding full-length RNA. To this end, 5 µg of RNA was electroporated into 5x10⁶ BHK-21 cells (for MERS-CoV) or BHK-21 cells expressing SARS-CoV N protein (for SARS-CoV and SARS-CoV-2; [99]) using the Amaxa nucleofactor 2b (program A-031) and Nucleofection T solution kit (Lonza). Transfected cells were mixed with HuH7 or Vero cells (for MERS-CoV) or Vero E6 cells (for SARS-CoV and SARS-CoV-2) in a 1:1 ratio and plated for harvesting supernatants, intracellular RNA isolation, and analysis by immunofluorescence microscopy. Immunolabelling was performed as described before [78], using antibodies recognizing double-stranded RNA (dsRNA; [100]) or SARS-CoV nsp4 [79, 101].

Cells were incubated at 37°C up to a maximum of 6 days post transfection (d p.t.). Supernatants were collected when full cytopathic effect was observed, at 3 d p.t. or at the end of the experiment. Virus titers were determined by plaque assay in HuH7 and Vero cells [102]. In order to confirm the presence of engineered mutations in viral progeny, HuH7 and Vero cells were infected with supernatants harvested from transfected cells and intracellular

RNA was isolated at 18 h post infection as described above. cDNA was synthesized by reverse transcription using RevertedAid H minus reverse transcriptase (ThermoFischer Scientific) and random hexamer primers (Promega), in combination with a primer targeting the 3' end of the viral genome. The full-length genome or the nsp14-coding region were amplified by PCR using MyTaq DNA polymerase (Bioline) and after purification the PCR product was sequenced by Sanger sequencing. Genome sequencing by NGS was performed as described before [79]. All work with live (recombinant) class-3 CoVs was done in a biosafety level 3 laboratory at Leiden University Medical Center.

Analysis of viral RNA synthesis

Isolation of intracellular RNA was performed by lysing infected cell monolayers with TriPure isolation reagent (Roche Applied Science) according to the manufacturer's instructions. After purification, intracellular RNA samples were loaded onto a 1.5% agarose gel containing 2.2 M formaldehyde, which was run overnight at low voltage overnight in MOPS buffer (10 mM MOPS (sodium salt) (pH 7), 5 mM sodium acetate, 1 mM EDTA). Dried agarose gels were used for direct detection of viral mRNAs by hybridization with a ³²P-labeled oligonucleotide probe (5'-GCAAATCATCTAATTAGCCTAATC-3') that is complementary to the 3'-terminal sequence of MERS-CoV genome and all subgenomic mRNAs. After hybridization, RNA bands were visualized (using exposure times of up to 28 days) and quantified by phosphorimaging using a Typhoon-9410 variable mode scanner (GE Healthcare) and ImageQuant TL software (GE Healthcare).

PCR primers and Taqman probes targeting ORF1a (junction of nsp2-nsp3 coding region), the nucleocapsid (N) protein gene, or the leader-body TRS junction of subgenomic mRNA3 were designed and analyzed for multiplex quality using Beacon Designer™ Software (Premier Biosoft). Reverse transcription (RT) was performed using RevertedAid H minus reverse transcriptase (ThermoFischer Scientific) and a mix of specific reverse primers targeting ORF1a, ORF8, or subgenomic RNA 3 (primer sequences used available upon request). The mRNA derived from the cellular β -actin gene was used as a reference housekeeping gene. Tagged primers were used to differentiate between positive- and negative-stranded viral RNA. Samples were assayed by Taqman multiplex real-time PCR using TaqMan Universal Master Mix II and a CFX384 Touch™ Real Time PCR detection system (BioRad). A standard curve was obtained using an *in vitro* transcript derived from a synthetic plasmid that contained all PCR targets. cDNA was obtained as described above. Each RNA sample was analyzed in triplicate.

Plaque reduction assay

HuH7 cells seeded in 6-well clusters were infected with recombinant MERS-CoV at low m.o.i. (30 PFU/well) for 1 h at 37°C. Subsequently, the inoculum was replaced with 2 ml of a 1.2% suspension of Avicel (RC-581; FMC Biopolymer [103]) in DMEM (containing 2% FCS and antibiotics) and serial dilutions of 5-FU (F6627, Sigma-Aldrich) or Ribavirin (R9644, Sigma-Aldrich) ranging from 0 to 400 μ M. Cells were incubated at 37°C for 72 h, fixed with 7.4% formaldehyde, and plaques were visualized using crystal violet staining.

To compare the effect of 5-FU treatment on the progeny titers of wt and nsp14-E191D rMERS-CoV, confluent monolayers of HuH7 were incubated for 30 min at 37°C with solvent or a range of 5-FU concentrations. The drug was then removed and cells were infected at an m.o.i. of 0.1 during 1 h at 37°C. After removal of the inoculum, EMEM containing 2% FCS and solvent or a matching concentration of 5-FU was added to the wells. Supernatants were collected after 30h and rMERS-CoV progeny titers were determined by plaque assay. All drug-treated samples were normalized to the untreated vehicle control, and values were expressed as fold change compared to untreated virus titers.

Expression and purification of recombinant CoV nsps

SARS-CoV nsp10 and nsp14 were produced as described before [25] and used as a positive control in all biochemical assays. MERS-CoV nsp10 was expressed using pET30a vector and purified as described in [86, 104]. All MERS-CoV nsp14 constructs were cloned into expression vector pDEST14 with an N-terminal His₆-tag using the Gateway system [25]. MERS-CoV nsp14 mutant expression plasmids were generated by Quikchange site-directed mutagenesis using Accuzyme DNA polymerase (Bioline) following the manufacturer's instructions. pDEST14 plasmids expressing MERS-CoV nsp14 were transformed into competent *E. coli* strain Rosetta (DE3) pLyS (Novagen) and cultured in Luria-Bertani (LB) broth supplemented with 100 μ g/ ml of ampicillin and 30 μ g/ ml of chloramphenicol. Protein expression was induced at an optical density (OD_{600nm}) of 0.8 by adding 50 μ M of isopropyl- β -D-a-thiogalactopyranoside (IPTG; Bioline). After 24 h at 13°C, induced cells were harvested and lysed in a buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM β -mercaptoethanol, 5% glycerol, 1 mM PMSF, and 20 mM imidazole [105]. Next, the lysate was centrifuged at 12,000xg for 30 min, and the soluble fraction was column-purified by immobilized metal ion affinity chromatography using Nickel sepharose high performance beads (17526802, GE Healthcare). The eluate was fractionated by gel filtration on a Superdex-200 Increase 10/300GL column (GE Healthcare) in buffer containing 30 mM HEPES, pH 7.5, 300 mM NaCl, and 5% glycerol. In the end, proteins were concentrated using ultrafiltration devices with a molecular mass cut-off of 30 kDa

(Millipore), and protein concentrations were measured using spectrophotometry. All purified proteins were analyzed by SDS-PAGE followed by Coomassie blue staining as well as by Western blot using a mouse monoclonal antibody against the 6xHis-Tag (Novagen). Protein aliquots were stored at -80°C in 50% glycerol (v/v) and used for enzymatic assays.

Exonuclease activity assay

Synthetic RNA H4 [26] was radiolabeled at its 5' end using T4 polynucleotide kinase (Epicentre) and [γ - 32 P]ATP (Perkin Elmer) [79]. Unless stated otherwise in figures or legends, reactions contained 200 nM of recombinant nsp14, 800 nM of nsp10, and 750 nM of radiolabeled substrate in 40 mM Tris-HCl pH 7.5 containing 5 mM of MgCl₂ and 1 mM of DTT. After incubation at 37°C for up to 90min, reactions were stopped by addition of an equal volume of loading buffer containing 96% formamide and 10mM EDTA. Samples were then loaded on 7M urea-containing 20% (wt/vol) polyacrylamide gels (acrylamide/bisacrylamide ratio 19:1) buffered with 0.5x Tris-borate-EDTA and run at high voltage (1600 V). Results were visualized by phosphorimaging as described above.

N7-methyltransferase activity assay

Methyltransferase assays were performed in 40 mM Tris-HCl, pH 8.0, 5 mM DTT, 2 μ M of 7 MeGpppA or GpppA RNA cap analogue (New England Biolabs), 10 μ M adenosyl-methionine (AdoMet, Thermofisher), 0.03 μ Ci/ μ l [3 H]AdoMet (PerkinElmer) [25]. In each reaction, MERS-CoV or SARS-CoV nsp14 was added to a final concentration of 500 or 250 nM, respectively. Reactions were incubated at 30°C for up to 120min, and were stopped by the addition of 10-fold volume of 100 μ M ice-cold Adenosyl-Homocysteine (AdoHcy; ThermoFischer). Then, samples were spotted on a DEAE filter mat (PerkinElmer) pre-wet with Tris-HCl pH 8.0 buffer. Filter mats were washed twice with 10 mM ammonium formate (Sigma-Aldrich), pH 8.0, twice with MiliQ water, and once with absolute ethanol (Sigma-Aldrich). After air drying for 10 min, filter mats were cut and relevant pieces transferred to individual tubes. Betaplate scintillation fluid (PerkinElmer) was added and the amount of 3 H-label bound was measured in counts per minute (cpm) using a Wallac scintillation counter. For relative quantification, incorporation measurements for mutant proteins were normalized to values obtained with the wt control nsp14. Samples were measured in duplicate in each experiment.

ACKNOWLEDGMENTS

N.S.O. was supported by the Marie Skłodowska-Curie ETN European Training Network 'ANTIVIRALS' (EU Grant Agreement No. 642434). C.C.P and E.J.S. were supported in part by TOP-GO grant 700.10.352 from the Netherlands Organization for Scientific Research and by the SCORE project (EU Horizon 2020 research and innovation program, grant agreement 101003627). We thank Linda Boomaars for providing SARS- and MERS-CoV nsp10 and nsp14 expression constructs and Igor Sidorov for NGS assistance. We are indebted to Volker Thiel and colleagues (Institute of Virology and Immunology, Bern, Switzerland) for sharing their SARS-CoV-2 reverse genetics system and to Deyin Guo and colleagues (Wuhan University, China) for sharing their pET30-MERS-CoV-nsp10 expression vector. We are grateful to Etienne Decroly, Francois Ferron, and Bruno Canard (University of Aix-Marseille, France) for helpful discussions. We kindly acknowledge the sharing of unpublished information on IBV ExoN knockout mutants by Dr. Erica Bickerton and colleagues (Pirbright Institute, U.K.).

REFERENCES

1. Vignuzzi, M., et al., *Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population*. Nature, 2006. **439**(7074): p. 344-348.
2. Eigen, M. and P. Schuster, *The hypercycle. A principle of natural self-organization. Part A: Emergence of the hypercycle*. Naturwissenschaften, 1977. **64**(11): p. 541-65.
3. Domingo, E., J. Sheldon, and C. Perales, *Viral quasispecies evolution*. Microbiol Mol Biol Rev, 2012. **76**(2): p. 159-216.
4. Sanjuan, R., *Mutational fitness effects in RNA and single-stranded DNA viruses: common patterns revealed by site-directed mutagenesis studies*. Philos Trans R Soc Lond B Biol Sci, 2010. **365**(1548): p. 1975-1982.
5. Sanjuan, R., et al., *Viral mutation rates*. J Virol, 2010. **84**(19): p. 9733-9748.
6. Steinhauer, D.A., E. Domingo, and J.J. Holland, *Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase*. Gene, 1992. **122**(2): p. 281-288.
7. Drake, J.W. and J.J. Holland, *Mutation rates among RNA viruses*. Proc Natl Acad Sci U S A, 1999. **96**(24): p. 13910-13913.
8. Eigen, M., *Error catastrophe and antiviral strategy*. Proc Natl Acad Sci U S A, 2002. **99**(21): p. 13374-13376.
9. Eigen, M., *Selforganization of matter and the evolution of biological macromolecules*. Naturwissenschaften, 1971. **58**(10): p. 465-523.
10. Nga, P.T., et al., *Discovery of the first insect nidovirus, a missing evolutionary link in the emergence of the largest RNA virus genomes*. PLoS Pathog, 2011. **7**(9): p. e1002215.
11. Lauber, C., et al., *The footprint of genome architecture in the largest genome expansion in RNA viruses*. PLoS Pathog, 2013. **9**(7): p. e1003500.
12. Saberi, A., et al., *A planarian nidovirus expands the limits of RNA genome size*. PLoS Pathog, 2018. **14**(11): p. e1007314.
13. Bukhari, K., et al., *Description and initial characterization of metatranscriptomic nidovirus-like genomes from the proposed new family Abysoviridae, and from a sister group to the Coronavirinae, the proposed genus Alphaletovirus*. Virology, 2018. **524**: p. 160-171.
14. Snijder, E.J., et al., *Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage*. J Mol Biol, 2003. **331**(5): p. 991-1004.
15. Zuo, Y. and M.P. Deutscher, *Exoribonuclease superfamilies: structural analysis and phylogenetic distribution*. Nucleic Acids Res, 2001. **29**(5): p. 1017-1026.
16. Deutscher, M.P. and C.W. Marlor, *Purification and characterization of Escherichia coli RNase T*. J Biol Chem, 1985. **260**(11): p. 7067-7071.
17. Beese, L.S. and T.A. Steitz, *Structural basis for the 3'-5' exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism*. EMBO J, 1991. **10**(1): p. 25-33.
18. Steitz, T.A. and J.A. Steitz, *A general two-metal-ion mechanism for catalytic RNA*. Proc Natl Acad Sci U S A, 1993. **90**(14): p. 6498-6502.
19. Minskaia, E., et al., *Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis*. Proc Natl Acad Sci U S A, 2006. **103**(13): p. 5108-5113.
20. Ma, Y., et al., *Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex*. Proc Natl Acad Sci U S A, 2015. **112**(30): p. 9436-9441.

21. Ferron, F., et al., *Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA*. Proc Natl Acad Sci U S A, 2018. **115**(2): p. E162-E171.
22. Eckerle, L.D., et al., *High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants*. J Virol, 2007. **81**(22): p. 12135-12144.
23. Eckerle, L.D., et al., *Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing*. PLoS Pathog, 2010. **6**(5): p. e1000896.
24. Graham, R.L., et al., *A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease*. Nat Med, 2012. **18**(12): p. 1820-1826.
25. Bouvet, M., et al., *In vitro reconstitution of SARS-coronavirus mRNA cap methylation*. PLoS Pathog, 2010. **6**(4): p. e1000863.
26. Bouvet, M., et al., *RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex*. Proc Natl Acad Sci U S A, 2012. **109**(24): p. 9372-9377.
27. Subissi, L., et al., *One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities*. Proc Natl Acad Sci U S A, 2014. **111**(37): p. E3900-E3909.
28. Smith, E.C., et al., *Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics*. PLoS Pathog, 2013. **9**(8): p. e1003565.
29. Graepel, K.W., et al., *Proofreading-deficient coronaviruses adapt for increased fitness over long-term passage without reversion of exoribonuclease-inactivating mutations*. MBio, 2017. **8**(6): p. e01503-01517.
30. Gribble, J., et al., *The coronavirus proofreading exoribonuclease mediates extensive viral recombination*. bioRxiv, 2020: p. 2020.04.23.057786.
31. Yekwa, E., et al., *Arenaviridae exoribonuclease presents genomic RNA edition capacity*. bioRxiv, 2019: p. 541698.
32. Hastie, K.M., et al., *Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression*. Proc Natl Acad Sci U S A, 2011. **108**(6): p. 2396-2401.
33. Russier, M., et al., *The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses*. J Virol, 2014. **88**(23): p. 13811-13820.
34. Becares, M., et al., *Mutagenesis of coronavirus nsp14 reveals its potential role in modulation of the innate immune response*. J Virol, 2016. **90**(11): p. 5399-5414.
35. Case, J.B., et al., *Murine hepatitis virus nsp14 exoribonuclease activity is required for resistance to innate immunity*. J Virol, 2018. **92**(1): p. e01531-17.
36. Chen, Y., et al., *Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase*. Proc Natl Acad Sci U S A, 2009. **106**(9): p. 3484-3489.
37. Jin, X., et al., *Characterization of the guanine-N7 methyltransferase activity of coronavirus nsp14 on nucleotide GTP*. Virus Res, 2013. **176**(1-2): p. 45-52.
38. Chen, Y., et al., *Structure-function analysis of severe acute respiratory syndrome coronavirus RNA cap guanine-N7-methyltransferase*. J Virol, 2013. **87**(11): p. 6296-6305.

39. Case, J.B., et al., *Mutagenesis of S-adenosyl-L-methionine-binding residues in coronavirus nsp14 N7-methyltransferase demonstrates differing requirements for genome translation and resistance to innate immunity*. J Virol, 2016. **90**(16): p. 7248-7256.
40. Li, X., et al., *Bat origin of a new human coronavirus: there and back again*. Sci China Life Sci, 2020. **63**(3): p. 461-462.
41. Pyrc, K., B. Berkhout, and L. van der Hoek, *Identification of new human coronaviruses*. Expert Rev Anti Infect Ther, 2007. **5**(2): p. 245-253.
42. Munster, V.J., et al., *A novel coronavirus emerging in China - key questions for impact assessment*. N Engl J Med, 2020. **382**(8): p. 692-694.
43. Zhou, P., et al., *A pneumonia outbreak associated with a new coronavirus of probable bat origin*. Nature, 2020. **579**(7798): p. 270-273.
44. Zaki, A.M., et al., *Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia*. N Engl J Med, 2012. **367**(19): p. 1814-1820.
45. Cotten, M., et al., *Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus*. mBio, 2014. **5**(1): p. e01062-13.
46. Rabaan, A.A., et al., *Dynamics of scientific publications on the MERS-CoV outbreaks in Saudi Arabia*. J Infect Public Health, 2017. **10**(6): p. 702-710.
47. Farag, E., et al., *Drivers of MERS-CoV Emergence in Qatar*. Viruses, 2018. **11**(1): p. 22.
48. Al-Tawfiq, J.A. and Z.A. Memish, *Drivers of MERS-CoV transmission: what do we know?* Expert Rev Respir Med, 2016. **10**(3): p. 331-338.
49. Siddell, S.G., et al., *Additional changes to taxonomy ratified in a special vote by the International Committee on Taxonomy of Viruses (October 2018)*. Arch Virol, 2019. **164**(3): p. 943-946.
50. Gorbalenya, A., et al., *The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2*. Nat Microbiol, 2020. **5**(4): p. 536-544.
51. Yoshimoto, F.K., *The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19*. Protein J, 2020. **39**(3): p. 198-216.
52. Sievers, F., et al., *Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega*. Mol Syst Biol, 2011. **7**: p. 539.
53. Waterhouse, A.M., et al., *Jalview Version 2--a multiple sequence alignment editor and analysis workbench*. Bioinformatics, 2009. **25**(9): p. 1189-1191.
54. Almazan, F., et al., *Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate*. mBio, 2013. **4**(5): p. e00650-13.
55. Rabouw, H.H., et al., *Middle East respiratory coronavirus accessory protein 4a inhibits PKR-mediated antiviral stress responses*. PLoS Pathog, 2016. **12**(10): p. e1005982.
56. van Boheemen, S., et al., *Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans*. MBio, 2012. **3**(6): p. e00473-12.
57. Chan, J.F., et al., *Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation*. J Infect Dis, 2013. **207**(11): p. 1743-1752.
58. Raj, V.S., et al., *Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC*. Nature, 2013. **495**(7440): p. 251-254.

59. Eckerle, L.D., et al., *Effects of mutagenesis of murine hepatitis virus nsp1 and nsp14 on replication in culture*. Adv Exp Med Biol, 2006. **581**: p. 55-60.
60. Habjan, M., et al., *T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus*. J Gen Virol, 2008. **89**(Pt 9): p. 2157-2166.
61. Thao, T.T.N., et al., *Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform*. Nature, 2020.
62. Thiel, V., et al., *Multigene RNA vector based on coronavirus transcription*. J Virol, 2003. **77**(18): p. 9790-9798.
63. Scobey, T., et al., *Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus*. Proc Natl Acad Sci U S A, 2013. **110**(40): p. 16157-16162.
64. Bernad, A., et al., *A conserved 3'----5' exonuclease active site in prokaryotic and eukaryotic DNA polymerases*. Cell, 1989. **59**(1): p. 219-228.
65. Ogando, N.S., et al., *The curious case of the nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity*. Front Microbiol, 2019. **10**: p. 1813.
66. Neuman, B.W., et al., *Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3*. J Virol, 2008. **82**(11): p. 5279-5294.
67. Neuman, B.W., *Bioinformatics and functional analyses of coronavirus nonstructural proteins involved in the formation of replicative organelles*. Antiviral Res, 2016. **135**: p. 97-107.
68. Lei, J., Y. Kusov, and R. Hilgenfeld, *Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein*. Antiviral Res, 2018. **149**: p. 58-74.
69. Noordhuis, P., et al., *5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers*. Ann Oncol, 2004. **15**(7): p. 1025-1032.
70. Greenhalgh, D.A. and J.H. Parish, *Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells*. Br J Cancer, 1990. **61**(3): p. 415-419.
71. Abbehausen, C., *Zinc finger domains as therapeutic targets for metal-based compounds - an update*. Metallomics, 2019. **11**(1): p. 15-28.
72. Imanishi, M., et al., *Zn(II) binding and DNA binding properties of ligand-substituted CXHH-type zinc finger proteins*. Biochemistry, 2012. **51**(16): p. 3342-3348.
73. Chen, P., et al., *Biochemical characterization of exoribonuclease encoded by SARS coronavirus*. J Biochem Mol Biol, 2007. **40**(5): p. 649-655.
74. Baddock, H.T., et al., *Characterisation of the SARS-CoV-2 ExoN (nsp14 ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification*. bioRxiv, 2020: p. 2020.08.13.248211.
75. Bouvet, M., et al., *Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes*. J Biol Chem, 2014. **289**(37): p. 25783-25796.
76. Rosas-Lemus, M., et al., *The crystal structure of nsp10-nsp16 heterodimer from SARS-CoV-2 in complex with S-adenosylmethionine*. bioRxiv, 2020: p. 2020.04.17.047498.
77. de Wilde, A.H., et al., *Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model*. Virus Res, 2017. **228**: p. 7-13.
78. de Wilde, A.H., et al., *MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment*. J Gen Virol, 2013. **94**(Pt 8): p. 1749-60.

79. Ogando, N.S., et al., *SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology*. J Gen Virol, 2020.
80. Graepel, K.W., et al., *Fitness barriers limit reversion of a proofreading-deficient coronavirus*. J Virol, 2019. **93**(20): p. e00711-19.
81. Kirchdoerfer, R.N. and A.B. Ward, *Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors*. Nat Commun, 2019. **10**(1): p. 2342.
82. Yin, W., et al., *Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir*. Science, 2020. **368**(6498): p. 1499-1504.
83. Hillen, H.S., et al., *Structure of replicating SARS-CoV-2 polymerase*. Nature, 2020. **584**(7819): p. 154-156.
84. Barnes, M.H., et al., *The 3'-5' exonuclease site of DNA polymerase III from gram-positive bacteria: definition of a novel motif structure*. Gene, 1995. **165**(1): p. 45-50.
85. Pan, J., et al., *Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV replication*. PLoS One, 2008. **3**(10): p. e3299.
86. Wang, Y., et al., *Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis*. J Virol, 2015. **89**(16): p. 8416-27.
87. Derbyshire, V., N.D. Grindley, and C.M. Joyce, *The 3'-5' exonuclease of DNA polymerase I of Escherichia coli: contribution of each amino acid at the active site to the reaction*. EMBO J, 1991. **10**(1): p. 17-24.
88. Durzynska, I., et al., *Characterization of a bafinivirus exoribonuclease activity*. J Gen Virol, 2018. **99**(9): p. 1253-1260.
89. Kindler, E. and V. Thiel, *To sense or not to sense viral RNA--essentials of coronavirus innate immune evasion*. Curr Opin Microbiol, 2014. **20**: p. 69-75.
90. Knoop, K., et al., *SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum*. PLoS Biol, 2008. **6**(9): p. e226.
91. Snijder, E.J., et al., *A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis*. PLoS Biol, 2020. **18**(6): p. e3000715.
92. Wolff, G., et al., *A molecular pore spans the double membrane of the coronavirus replication organelle*. Science, 2020.
93. Ulferts, R., T.C. Mettenleiter, and J. Ziebuhr, *Characterization of Bafinivirus main protease autoprocessing activities*. J Virol, 2011. **85**(3): p. 1348-1359.
94. Snijder, E.J., E. Decroly, and J. Ziebuhr, *The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing*. Adv Virus Res, 2016. **96**: p. 59-126.
95. Nedialkova, D.D., A.E. Gorbalenya, and E.J. Snijder, *Arterivirus Nsp1 modulates the accumulation of minus-strand templates to control the relative abundance of viral mRNAs*. PLoS Pathog, 2010. **6**(2): p. e1000772.
96. Tischer, B.K., G.A. Smith, and N. Osterrieder, *En passant mutagenesis: a two step markerless red recombination system*. Methods Mol Biol, 2010. **634**: p. 421-430.
97. Pfefferle, S., et al., *Reverse genetic characterization of the natural genomic deletion in SARS-Coronavirus strain Frankfurt-1 open reading frame 7b reveals an attenuating function of the 7b protein in-vitro and in-vivo*. Virol J, 2009. **6**: p. 131.
98. Wu, F., et al., *A new coronavirus associated with human respiratory disease in China*. Nature, 2020. **579**(7798): p. 265-269.

99. Chang, G.H., et al., *Establishment of the eukaryotic cell lines for inducible control of SARS-CoV nucleocapsid gene expression*. Virol Sin, 2010. **25**(5): p. 361-368.
100. Weber, F., et al., *Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses*. J Virol, 2006. **80**(10): p. 5059-5064.
101. van Hemert, M.J., et al., *SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro*. PLoS Pathog, 2008. **4**(5): p. e1000054.
102. van den Worm, S.H., et al., *Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination*. PLoS One, 2012. **7**(3): p. e32857.
103. Matrosovich, M., et al., *New low-viscosity overlay medium for viral plaque assays*. Virol J, 2006. **3**: p. 63.
104. Chen, Y., et al., *Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex*. PLoS Pathog, 2011. **7**(10): p. e1002294.
105. Aouadi, W., et al., *Toward the identification of viral cap-methyltransferase inhibitors by fluorescence screening assay*. Antiviral Res, 2017. **144**: p. 330-339.

